These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 7477586

  • 1. [Treatment and prevention of generalized mycoses].
    van der Spoel JI.
    Ned Tijdschr Geneeskd; 1995 Oct 21; 139(42):2164-5. PubMed ID: 7477586
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P, Thamlikitkul V.
    J Med Assoc Thai; 2006 Nov 21; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Amphotericin B: effective management of adverse reactions.
    Anderson M, Faulkner N.
    Cancer Nurs; 1982 Dec 21; 5(6):461-3. PubMed ID: 6924601
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.
    Altmannsberger P, Holler E, Andreesen R, Krause SW.
    J Antimicrob Chemother; 2007 Jul 21; 60(1):180-2. PubMed ID: 17537868
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.
    Paterson DL, David K, Mrsic M, Cetkovsky P, Weng XH, Sterba J, Krivan G, Boskovic D, Lu M, Zhu LP, PRoACT Investigators.
    J Antimicrob Chemother; 2008 Dec 21; 62(6):1392-400. PubMed ID: 18812423
    [Abstract] [Full Text] [Related]

  • 18. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management.
    Collazos J, Martínez E, Mayo J, Ibarra S.
    Clin Infect Dis; 2001 Oct 01; 33(7):E75-82. PubMed ID: 11528589
    [Abstract] [Full Text] [Related]

  • 19. Lipid formulations of amphotericin B.
    Dix SP, Andriole VT.
    Curr Clin Top Infect Dis; 2000 Oct 01; 20():1-23. PubMed ID: 10943516
    [Abstract] [Full Text] [Related]

  • 20. Amphotericin B: Ten common questions.
    Comer JB.
    Am J Nurs; 1981 Jun 01; 81(6):1166-7. PubMed ID: 6909008
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.